Healthcare solutions company Evolent Health (NYSE:EVH) reported Q1 CY2025 results exceeding the market’s revenue expectations , but sales fell by 24.4% year on year to $483.6 million. Revenue guidance for the full year exceeded analysts’ estimates, but next quarter’s guidance of $455 million was less impressive, coming in 9.4% below expectations. Its non-GAAP profit of $0.06 per share was 33% below analysts’ consensus estimates.
Is now the time to buy EVH? Find out in our full research report (it’s free).
Revenue: $483.6 million vs analyst estimates of $461.2 million (24.4% year-on-year decline, 4.9% beat)
Adjusted EPS: $0.06 vs analyst expectations of $0.10 (33% miss)
Adjusted EBITDA: $36.86 million vs analyst estimates of $33.82 million (7.6% margin, 9% beat)
The company reconfirmed its revenue guidance for the full year of $2.09 billion at the midpoint
EBITDA guidance for the full year is $150 million at the midpoint, in line with analyst expectations
Operating Margin: -0.3%, up from -2.1% in the same quarter last year
Sales Volumes rose 6.6% year on year (19.5% in the same quarter last year)
Market Capitalization: $982.5 million
Evolent Health’s first quarter performance was shaped by evolving customer demand for specialty condition management and continued expansion within its core product areas. CEO Seth Blackley highlighted the company’s addition of five new revenue agreements across oncology, musculoskeletal, and surgical management lines, attributing these wins to Evolent Health’s ability to address complex clinical needs for both new and existing clients. The company also completed contractual transitions impacting its revenue mix, most notably shifting certain Performance Suite contracts from gross to net accounting, while maintaining strong renewal rates with major health plan partners. Management called out initial traction for its AuthIntel AI automation solution, noting early improvements in clinician satisfaction and process efficiency. Despite these operational gains, leadership acknowledged the quarter’s underlying margin improvement was not fully realized in reported figures, as claims trends and contract transitions continued to influence financial results.
Looking forward, management emphasized a focus on scaling its new oncology navigation platform and further integrating automation to drive both growth and profitability. Seth Blackley stated, “Our oncology navigation solution combines internally developed protocols, digital tools, and newly acquired navigation assets to deliver a more comprehensive care management experience.” The company expects these innovations to expand its addressable market and enhance value delivered to health plan clients, particularly as payers seek solutions to manage rising specialty care costs. CFO John Johnson noted that Evolent Health is closely monitoring medical cost trends, particularly in oncology, but will not update its guidance until additional claims data provides a clearer trend. The leadership team also highlighted ongoing efforts to optimize contract structures and automate claim reviews, aiming to accelerate operational efficiencies and improve member outcomes in the coming quarters.
Management attributed the quarter’s outcomes to contract transitions, new business wins in specialty management, and the initial rollout of AI-driven automation, while also launching a major oncology navigation platform.
Contract transitions impacted revenue: The shift of certain Performance Suite contracts from gross to net accounting influenced reported revenue, with CFO John Johnson explaining these changes were anticipated and EBITDA-neutral, but temporarily inflated topline results.
Specialty management platform growth: Five new agreements were signed, including first-time contracts for surgical management with national and regional health plans, and geographic expansion of oncology and musculoskeletal solutions with existing clients, resulting in approximately 1 million additional covered lives.
Oncology navigation launch: Evolent Health officially launched its integrated oncology navigation solution, combining in-house protocols, newly acquired navigation assets from Oncology Care Partners, and the Careology digital app. Management reported early client deployments and indicated this offering could increase savings opportunities by 10-20% compared to prior solutions.
AI and automation adoption: The company deployed its AuthIntel AI tool to streamline clinical review processes, delivering faster patient resolutions and improved clinician satisfaction. While still early, management sees significant long-term opportunity for automation to boost productivity and reduce manual workload.
Performance Suite margin maturation: Margin improvement initiatives are underway, with management noting favorable leading indicators in oncology cost trends, though full benefit realization awaits more complete claims data. John Johnson emphasized that annual contract repricing and corridor structures are helping maintain margin stability across evolving payer mixes.
Evolent Health’s outlook is driven by scaling its oncology navigation solution, increasing automation, and maintaining disciplined contract management to navigate evolving policy and industry trends.
Oncology navigation platform scaling: Management expects broader adoption of the integrated oncology navigation solution to increase the value delivered to clients, citing early evidence of improved patient engagement and potential for expanded savings, especially as the offering addresses both clinical and non-clinical aspects of cancer care.
AI-driven productivity gains: Leadership anticipates that further automation of claims reviews and clinical workflows will reduce processing times and operational costs through 2025 and beyond, while reiterating that AI is used only to support approvals and not to restrict access to care.
Policy and payer dynamics: The company is monitoring potential policy changes in Medicare and Medicaid but expects limited near-term impact due to contract structures allowing for rate adjustments if drug costs rise. Diversification across payer types and continued annual repricing cycles are expected to help buffer against macro and regulatory headwinds.
In the coming quarters, the StockStory team will watch (1) the pace and client uptake of the new oncology navigation platform, (2) evidence of sustained margin improvement from expanding automation and contract repricing, and (3) any shifts in medical cost trends—particularly in oncology and cardiology—that could influence guidance updates. Additional focus will be on the company’s execution of planned Performance Suite go-lives and integration of newly acquired assets.
Evolent Health currently trades at a forward P/E ratio of 15.3×. Is the company at an inflection point that warrants a buy or sell? The answer lies in our full research report (it’s free).
The market surged in 2024 and reached record highs after Donald Trump’s presidential victory in November, but questions about new economic policies are adding much uncertainty for 2025.
While the crowd speculates what might happen next, we’re homing in on the companies that can succeed regardless of the political or macroeconomic environment. Put yourself in the driver’s seat and build a durable portfolio by checking out our Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.
